In Thousand Oaks, California, AliveGen USA Inc. has announced the successful conclusion of its Phase 1b multiple-ascending dose (MAD) clinical trial for the novel drug ALG-801.

Rezatapopt is a groundbreaking targeted therapy for advanced solid tumors with the TP53 Y220C mutation and KRAS wild-type.

Gunda Georg, co-creator of YCT-529, presented an update on the phase 1a clinical trial of the novel hormone-free male contraceptive pill at the American Chemical Society's Spring Meeting in New Orleans

DepYmed Inc. has announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) to begin phase 1 clinical trials for DPM-1003.

Recce Pharmaceuticals has recently completed a new phase of clinical trials for its lead drug candidate, RECCE® 327.

The trial is assessing the efficacy of Deltacel™ (KB-GDT-01), an allogeneic, readily available Gamma Delta T-cell (GDT) therapy for patients with stage 4 metastatic non-small cell lung cancer (NSCLC).

Biotechnology firm Jasper Therapeutics has initiated its Phase 1b/2a clinical trial, for the treatment of chronic inducible urticaria (CIndU) using a novel antibody, briquilimab.

Celularity Inc. has submitted an application to the U.S. Food and Drug Administration (FDA) for orphan drug designation for PDA-002, its placental-derived cell therapy.

A clinical trial has been initiated for an innovative drug candidate, 23ME-01473, developed by 23andMe Holding Co., a prominent entity in human genetics and biopharmaceuticals.

Significant advancements have been observed in the treatment of thyroid eye disease (TED) with lonigutamab, a humanized monoclonal antibody.

Inhalon Biopharma, a company in the clinical stage, has revealed initial findings from a pivotal Phase 1b clinical trial.

Antennova, a biopharmaceutical firm, has reached a significant milestone with the completion of the initial dosing group in a Phase I clinical trial for ATN-031.